Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid,
rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to …

Mycobacterium tuberculosis (Mtb) lipids are indelibly imprinted in just about every key
aspect of tuberculosis (TB) basic and translational research. Although the interest in these …

Decaprenylphosphoryl-β-d-ribose 2′-epimerase (DprE1) is a critical flavoenzyme in
Mycobacterium tuberculosis, catalyzing a vital step in the production of lipoarabinomannan …

Eighty years after the introduction of the first antituberculosis (TB) drug, the treatment of drug-
susceptible TB remains very cumbersome, requiring the use of four drugs (isoniazid …

Decaprenylphosphoryl-β-d-ribose 2′-epimerase (DprE1), a vital enzyme for cell wall
synthesis, plays a crucial role in the formation of lipoarabinomannan and arabinogalactan. It …

Current antibiotics, derived mainly from natural sources, inhibit a narrow spectrum of cellular
processes, namely DNA replication, protein synthesis, and cell wall biosynthesis. With the …

The benzothiazinone BTZ043 is a tuberculosis drug candidate with nanomolar whole-cell
activity. BTZ043 targets the DprE1 catalytic component of the essential enzyme …

Tuberculosis (TB) remains the second most common cause of death due to a single
infectious agent. The cell envelope of Mycobacterium tuberculosis (Mtb), the causative agent …

Tuberculosis (TB) is a global lethal disease caused by Mycobacterium tuberculosis (Mtb).
The flavoenzyme decaprenylphosphoryl-β-d-ribose 2′-oxidase (DprE1) plays a crucial part …

The expectation that genomics would result in new therapeutic interventions for infectious
diseases remains unfulfilled. In the post‐genomic era, the decade immediately following the …